US 2025/0085273 A1 · NOVEL RAPID DRUG DISCOVERY FOR SEPSIS AND AGENTS FOR USE AS SEPSIS THERAPY

Abstract

In this disclosure, a zebrafish model is established for rapid screening of potential drug candidates for prevention and treatment of sepsis. To this end, three endpoints (mortality, tail-fin edema, and reactive oxygen species detection) screening method is established to identify drugs of potential use among approved drugs and/or novel small molecules, and 16 drugs were identified, which target serotonin receptors, receptor tyrosine kinases, dietary supplements, antihistamine drugs, serotonin uptake inhibitors, monoamine oxidase inhibitors, and other antipsychotic drugs.

Claims40

Dependent claims

A method of preventing or treating severe inflammation, sepsis, and/or septic shock;

comprising a step of administering an effective amount of:
a. a drug that suppresses the activity of 5-hydroxytryptamine (5-HT, serotonin) receptors, to a subject in need of such treatment, wherein the drug optionally comprises one or more of an antagonist, a partial agonist, or an inverse agonist of 5-HT receptors;
b. a drug that inhibits the activity of receptor tyrosine kinases (RTKs), to a subject in need of such treatment, wherein the drug optionally comprises one or more of an inhibitor of platelet-derived growth factor receptors (PDGFRa and PDGFRb), vascular endothelial growth factor receptors (VEGFR1, VEGFR2 and VEGFR3), stem cell factor receptor (KIT), Fms-like tyrosine kinase-3 (FLT3), colony stimulating factor receptor Type 1 (CSF-1R), and/or the glial cell-line derived neurotrophic factor receptor (RET);
c. a dietary supplement comprising a folic acid supplement and/or iron supplement
d. a drug that suppresses the activity of histamine receptors, wherein the drug optionally comprises an antagonist, a partial agonist, or an inverse agonist of histamine receptors, wherein the histamine receptor is H1, H2, H3, or H4;
and/or
e. a drug that increases the level of 5-hydroxytryptamine (5-HT, serotonin) in blood, wherein the drug optionally comprises a selective serotonin reuptake inhibitor (SSRI), serotonin-norepinephrine reuptake inhibitors (SNRI), or monoamine oxidase inhibitor (MAOI).

4 more elements

Dependencies are inferred from the claim text.

Novel rapid drug discovery for sepsis and agents for use as sepsis therapy

Life of this patent

Novel rapid drug discovery for sepsis and agents for use as sepsis therapy

Life of this patent

Abstract

Claims40